Effect of OMM on Anandamide Levels in Saliva

Endocannabinoids Clinical Trial

Official title:

Osteopathic Manipulative Lymphatic Pump Technique and Its Effects to the Endocannabinoid System Activity as Measured by AEA Levels Via Mass Spectrometry and Mood Analogue Scale

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02727023
• Other study ID #: BHS-1152
• Status: Completed
• Phase: N/A
• First received: January 19, 2016
• Last updated: October 3, 2017
• Start date: December 2015
• Est. completion date: September 2017

Study information

• Verified date: October 2017
• Source: New York Institute of Technology
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The Investigators will be studying the effects of Osteopathic Manipulative Lymphatic Pump Treatment on levels of anandamide in Saliva. A qualitative scale will also be used to measure the canabinomimetic effects of osteopathic treatment.

Description:

The Endocannabinoid System is a signaling system composed of: 2 G-Protein coupled receptors (CB1 and CB2), substances acting on the cannabinoid receptors, and the enzymes and proteins involved in regulating endocannabinoids in tissue and at the receptors. The substances acting the cannabinoid receptors CB1 and CB2 are called endocannabinoids. The present study examines the effects of Osteopathic Manipulative Lymphatic Pump Techniques on levels of anandamide, an endocannabinoid, in saliva samples of adult subjects. Based on existing research, the investigators hypothesize that subjects who undergo osteopathic lymphatic treatment will have increased levels of anandamide. Establishing the levels of endocannabinoids in these subjects will allow for a direct measure of the efficacy of the Osteopathic Manipulative Lymphatic techniques. In addition to the quantification of endocannabinoid levels in saliva, a series of 16, 100 mm analog scales will be used to assess the cannabinomimetic effects in the subject pre and post OMM treatment/control and it will be correlated to changes in endocannabinoid levels.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 2
• Est. completion date: September 2017
• Est. primary completion date: August 2016
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Accepts healthy volunteers.

• Able to read and understand scale for survey.

• BMI (Body Mass Index) TBD- BMI between 18 and 25 kg/m2 Signed informed consent No exercising on the day of or day before the appointment Age 18 and above.

Exclusion Criteria:

• smoker

• Neuropsychiatric disorders

• Autoimmune Disorders

• Unavailable 8AM-12PM

• No Illicit drug use, including exogenous cannabis.

Related Conditions & MeSH terms

• Anandamide
• Endocannabinoids

Intervention

Other:
• Osteopathic Manipulative Medicine
The procedures are picked for their generalized effect on the lymphatic system based on osteopathic literature and research. Our goal is to mobilize the lymphatic fluid to induce an increase of endocannabinoids. These procedures are similar to mechanical motion seen in exercise in regards to lymphatic movement. Each technique will be performed for a total of four minutes each

Locations

Country	Name	City	State
United States	NYITCOM	Old Westbury	New York

Sponsors (2)

Lead Sponsor	Collaborator
New York Institute of Technology	Cold Spring Harbor Laboratory

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Osteopathic Manipulative Lymphatic Pump Treatment and Its Relationship To Anandamide levels	The Investigators will be studying the effects of Osteopathic Manipulative Lymphatic Pump Treatment on levels of anandamide in Saliva. A qualitative scale will also be used to measure the canabinomimetic effects of osteopathic treatment.	60 minutes